Trials / Completed
CompletedNCT02249988
Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B
Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 261 (actual)
- Sponsor
- Abivax S.A. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The study is an open-label, randomized, comparative, multicenter clinical trial. The purpose of this study is to assess the efficacy of ABX203, a new chronic hepatitis B therapeutic vaccine administered as an adjunct therapy to nucleos(t)ide analogs (NUCs), in maintaining control of Hepatitis B disease after cessation of treatment with NUCs in subjects with HBeAg negative chronic Hepatitis B.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABX203 therapeutic Hepatitis B vaccine treatment arm |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2014-09-26
- Last updated
- 2017-01-24
Locations
12 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT02249988. Inclusion in this directory is not an endorsement.